Annual CFI
$0.00
+$1.50 M+100.00%
December 31, 2023
Summary
- As of February 26, 2025, SLRX annual cash flow from investing activities is $0.00, with the most recent change of +$1.50 million (+100.00%) on December 31, 2023.
- During the last 3 years, SLRX annual CFI has risen by +$2600.00 (+100.00%).
- SLRX annual CFI is now -100.00% below its all-time high of $24.49 million, reached on December 31, 2017.
Performance
SLRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
N/A
September 30, 2024
Summary
- SLRX quarterly cash flow from investing activities is not available.
Performance
SLRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFI
N/A
September 30, 2024
Summary
- SLRX TTM cash flow from investing activities is not available.
Performance
SLRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
SLRX Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +100.0% | - | - |
| 3 y3 years | +100.0% | - | - |
| 5 y5 years | -100.0% | - | - |
SLRX Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +100.0% | ||||
| 5 y | 5-year | -100.0% | +100.0% | ||||
| alltime | all time | -100.0% | +100.0% |
Salarius Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $0.00(-100.0%) | - | - |
| Dec 2022 | -$1.50 M(<-9900.0%) | $0.00(0.0%) | -$1.50 M(0.0%) |
| Sep 2022 | - | $0.00(0.0%) | -$1.50 M(0.0%) |
| Jun 2022 | - | $0.00(-100.0%) | -$1.50 M(0.0%) |
| Mar 2022 | - | -$1.50 M(<-9900.0%) | -$1.50 M(<-9900.0%) |
| Dec 2021 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2021 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2021 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2021 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2020 | -$2600.00(-100.0%) | - | - |
| Dec 2019 | $5.61 M(-60.3%) | $0.00(-100.0%) | $5.61 M(-0.1%) |
| Sep 2019 | - | $5.61 M(>+9900.0%) | $5.61 M(+180.0%) |
| Mar 2019 | - | $0.00(-100.0%) | $2.00 M(-85.8%) |
| Dec 2018 | $14.12 M | $3400.00(>+9900.0%) | $14.12 M(-24.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $0.00(-100.0%) | $18.78 M(+135.2%) |
| Jun 2018 | - | $2.00 M(-83.5%) | $7.99 M(-73.1%) |
| Mar 2018 | - | $12.12 M(+160.0%) | $29.73 M(+21.4%) |
| Dec 2017 | $24.49 M(-300.1%) | $4.66 M(-143.2%) | $24.49 M(+18.2%) |
| Sep 2017 | - | -$10.80 M(-145.5%) | $20.71 M(-25.1%) |
| Jun 2017 | - | $23.74 M(+245.0%) | $27.64 M(-1603.0%) |
| Mar 2017 | - | $6.88 M(+677.5%) | -$1.84 M(-85.0%) |
| Dec 2016 | -$12.24 M(-55.1%) | $885.00 K(-122.8%) | -$12.24 M(-59.4%) |
| Sep 2016 | - | -$3.87 M(-32.4%) | -$30.16 M(-17.2%) |
| Jun 2016 | - | -$5.73 M(+62.8%) | -$36.44 M(+18.5%) |
| Mar 2016 | - | -$3.52 M(-79.3%) | -$30.76 M(+12.8%) |
| Dec 2015 | -$27.27 M | -$17.04 M(+67.8%) | -$27.27 M(+166.6%) |
| Sep 2015 | - | -$10.15 M(>+9900.0%) | -$10.23 M(>+9900.0%) |
| Jun 2015 | - | -$49.20 K(+86.4%) | -$75.60 K(+186.4%) |
| Mar 2015 | - | -$26.40 K | -$26.40 K |
FAQ
- What is Salarius Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals annual CFI year-on-year change?
- What is the all time high quarterly CFI for Salarius Pharmaceuticals?
- What is the all time high TTM CFI for Salarius Pharmaceuticals?
What is Salarius Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of SLRX is $0.00
What is the all time high annual CFI for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high annual cash flow from investing activities is $24.49 M
What is Salarius Pharmaceuticals annual CFI year-on-year change?
Over the past year, SLRX annual cash flow from investing activities has changed by +$1.50 M (+100.00%)
What is the all time high quarterly CFI for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high quarterly cash flow from investing activities is $23.74 M
What is the all time high TTM CFI for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high TTM cash flow from investing activities is $29.73 M